New Delhi: Piscium, an innovative nanotechnology startup specializing in medical devices, has raised Rs 6 crore in Series A round led by Unicorn India Ventures. The company, renowned for its patented nano-diamond technology, is also recognized by the Department of Scientific and Industrial Research (DSIR) as a leading dental and medical device startup.
The funds raised would be used for strengthening the sales & marketing team, brand building, scale up production & operations and launch international business.
Chronic & stress related diseases such as diabetes are undoubtedly on the rise in India and so are the frequency of dental ailments. With its path-breaking R&D in medical sciences, Piscium is creating a platform for reaching out to the largest patient pool for dentistry by manufacturing various dental products like Alpha Nano Diamond Burs, Epsilon Burs, Alginates and many more.
Piscium’s patented Nano Diamond Dental Burs, developed and commercialized by them, are the first of their kind in the world and are fast being adopted by dentists for their speed, accuracy, procedural control & smoothness. Due to these differentiating features, dentists have found specialized designs like fissurotomy and surgical burs to be particularly useful.
Piscium’s portfolio today consists of over 10 product categories which include a wide array of dental burs, dental alginates & other products. The company aims to build a diverse portfolio of dental and medical devices that empower healthcare professionals and positively impact the lives of patients worldwide.
Malay Dikshit, Founder & CEO, Piscium, says, “Unicorn India Ventures agreeing to come on board to fund our series A round gives us the much-needed impetus and backing to scale up the business into an internationally renowned dental and medical device company in the near future. We also wish to thank SINE-IITB, BIRAC, Friends and Investors who supported and invested in us in our early days. By 2027, over 300k dentists across 5 continents would be using Piscium’s products as we believe that scientific acumen, strong innovation pipeline and an equally strong route to market would be our principal growth drivers.”































































